ABSTRACT OBJECTIVES This study investigated the relationship between anti-factor Xa (anti-FXa) and activated partial thromboplastin time (aPTT) for monitoring intravenous unfractionated heparin (IV-UFH) in patients with continuous-flow left ventricular assist devices (CF-LVADs).
and heat dissipation from the bearings, coupled with inadequate anticoagulation, may be contributing factors (3) .
Intravenous unfractionated heparin (IV-UFH) has been the mainstay for bridging therapy and for the treatment of suspected device obstruction and hemolysis in patients with CF-LVADs. In light of the risk of early device thrombosis, there is an urgent need to re-examine the way in which IV-UFH treatment is monitored (1, 2) . Measurement of activated partial thromboplastin time (aPTT) has been the criterion standard. However, because aPTT is susceptible to physiological and nonphysiological factors that do not reflect intrinsic heparin activity, patients may receive unintentionally high or low doses of heparin (4).
In non-LVAD patients, anti-factor Xa (anti-FXa) has been suggested as an alternative measure because it may exhibit less variability and be less affected by other biological factors unrelated to UFH (5) (6) (7) (8) The anti-FXa therapeutic ranges used by our institution corresponded to 0.15 to 0.35 U/ml for low intensity and 0.3 to 0.7 U/ml for high intensity (12) (13) (14) ; this was our comparison group. The aPTT heparin therapeutic range was subsequently verified at annual lot changes For supratherapeutic anti-FXa levels >0.7 U/ml, the protocol specified holding infusion for 60 min, then a dose reduction by 300 U/h; for levels >1.31 U/ml, infusion was held for 60 min, then a dose reduction by 350 U/h. Subtherapeutic levels were rechecked after 6 h. For levels <0.1 U/ml, the protocol stipulated a bolus of 50 U/kg and a dose increase by 300 U/h; for levels 0.1 to 0.14 U/ml, the protocol called for a bolus To mitigate the effect of outliers, values were averaged from patients with >4 consecutive simultaneous specimens using a single value for each individual.
The coefficient of determination (r 2 ) was calculated to estimate the proportion of the variation in aPTT that could be accounted for by using anti-FXa.
RESULTS DEMOGRAPHIC AND CLINICAL CHARACTERISTICS.
A total of 340 samples from 38 patients with CF-LVADs were analyzed for concordance of anti-FXa and aPTT values. The patients' demographic and clinical characteristics are shown in Table 1 . Of the 163 samples from the 24 patients in the bridging cohort, anti-FXa and aPTT were concordant in 59 (36.2%) and discordant in 104 (63.8%) ( Table 3) . Other abbreviations as in Tables 1 and 2 . 
Anticoagulation Monitoring in CF-LVADs COMPARISON GROUP. In 59 patients without an LVAD who were selected at random, the mean anti- To evaluate the biochemical basis for discordance, coagulation factors II, V, VII, VIII, IX, X, XI, and XII Tables 1 and 2 . Abbreviations as in Tables 1 and 2 . Abbreviations as in Tables 1 and 2 .
Abbreviations as in
were measured simultaneously with anti-FXa and aPTT in 10 consecutive patients with discordant levels ( Table 6 ). All patients had a supratherapeutic aPTT compared with anti-FXa. Factor VIII was elevated in 9 of 10 patients. One had a low factor V value (58%), whereas 2 patients had low factor XII values. Low levels of factors II, VII, IX, and X were observed in patients receiving warfarin who had an elevated INR.
CLINICAL OUTCOMES. There were no significant differences between the bridging and suspected obstruction/hemolysis cohorts in major bleeding, thromboembolic events, or mortality at 30 days after IV-UFH administration ( Table 7) . Proportion of concordant and discordant sample pairs with a lactate dehydrogenase (LDH) concentration <2.5 or $2.5 times the upper limit of normal (750 U/l). Abbreviation as in Figure 1 .
Adatya et al. Normal assay ranges for factors II, V, VII, VIII, IX, X, and XI, 60% to 140%; factor XII, 50% to 186%; international normalized ratio (INR), 0.86 to 1.14; and lactate dehydrogenase (LDH), 325 to 750 U/l. Patient 9 was in the bridging cohort, and the remaining 9 patients were in the device obstruction/hemolysis cohort.
Other abbreviation as in Table 1 . (20) .
There is a complex interaction between factor XII levels and thrombosis, with no clear relationship;
however, data from a large registry revealed a U-shaped association of factor XII plasma levels with mortality from cardiovascular disease (20, 21) .
Furthermore, 9 of 10 patients tested had elevated levels of factor VIII, which is an independent marker of increased thrombotic risk and has been shown to be elevated in non-CF-LVAD patients with heparin resistance, lowering the aPTT and possibly leading to over-anticoagulation (17) . However, in our cohort, elevated factor VIII was not associated with heparin resistance; on the contrary, most patients had supratherapeutic aPTT levels despite a therapeutic anti-FXa. 
